{'fraction_non_alphanumeric': 0.0160857908847185, 'fraction_numerical': 0.0, 'mean_word_length': 5.225, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
New promise for autologous marrow transplants in leukemia.

In the past five years, the chances of successfully using autologous marrow transplants in cancers that may involve the marrow itself have been dramatically improved with the development of strategies for eradicating contaminating malignant cells from the autologous marrow inoculum. At several centers, attention has been focused on the use of monoclonal antibodies for the elimination of such malignant cells. Efficient killing of leukemic cells that contaminate marrow has been achieved when the marrow has been incubated in vitro with monoclonal antibodies and complement, or with monoclonal antibodies that have been chemically coupled to toxins such as ricin-A. In addition, . . .